

Duchenne Muscular Dystrophy: Identification, Management, Genetic Counseling, and the Multidisciplinary Care Team

Additional Reading/References

| Resource | Address |
|--|---|
| Andrews JG, Davis MF, Meaney FJ. Correlates of care for young men with Duchenne and Becker muscular dystrophy. <i>Muscle Nerve</i> . 2014;49:21-25. | https://pubmed.ncbi.nlm.nih.gov/23558904/ |
| Barnard AM, Riehl SL, Willcocks RJ, Walter GA, Angell AM, Vandenborne K. Characterizing enrollment in observational studies of Duchenne muscular dystrophy by race and ethnicity. <i>J Neuromuscul Dis</i> . 2020;7:167-173. | https://pubmed.ncbi.nlm.nih.gov/31929119/ |
| Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: Disease mechanism and therapeutic strategies. <i>Front Physiol</i> . 2023;14:1183101. | https://pubmed.ncbi.nlm.nih.gov/37435300/ |
| Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. <i>Lancet Neurol</i> . 2018;17:251-267. | https://pubmed.ncbi.nlm.nih.gov/29395989/ |
| Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management. <i>Lancet Neurol</i> . 2018;17:347-361. | https://pubmed.ncbi.nlm.nih.gov/29395990/ |
| Birnkrant DJ, Bushby K, Bann C M, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan. <i>Lancet Neurol</i> . 2018;17:445-455. | https://pubmed.ncbi.nlm.nih.gov/29398641/ |
| Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: Pathogenesis and promising therapies. <i>J Neurol</i> . 2023;270:3733-3749. | https://pubmed.ncbi.nlm.nih.gov/37258941/ |
| Ciafaloni E, Kumar A, Liu K, Salvo F, Messina S, Trifirò G. Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker muscular dystrophy: Data from the MD STARnet. <i>J Pediatr Rehabil Med</i> . 2016;9:5-11. | https://pubmed.ncbi.nlm.nih.gov/26966795/ |
| Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. <i>Orphanet J Rare Dis</i> . 2020;15:141. | https://pubmed.ncbi.nlm.nih.gov/32503598/ |
| Deng J, Zhang J, Shi K, Liu Z. Drug development progress in Duchenne muscular dystrophy. <i>Front Pharmacol</i> . 2022;13:950651. | https://pubmed.ncbi.nlm.nih.gov/35935842/ |
| Duan D. Duchenne muscular dystrophy gene therapy in 2023: Status, perspective, and beyond. <i>Hum Gene Ther</i> . 2023;34:345-349. | https://pubmed.ncbi.nlm.nih.gov/37219994/ |

| | |
|--|---|
| Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. <i>Nat Rev Dis Primers</i> . 2021;7:13. | https://pubmed.ncbi.nlm.nih.gov/33602943/ |
| Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. <i>J Neuromuscul Dis</i> . 2021;8(suppl 2):S303-S316. | https://pubmed.ncbi.nlm.nih.gov/34511510/ |
| Mann JR, Zhang Y, McDermott S, et al. Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne muscular dystrophy. <i>Neuroepidemiology</i> . 2023;57:90-99. | https://pubmed.ncbi.nlm.nih.gov/36623491/ |
| Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. <i>Lancet Neurol</i> . 2022;21:814-829. | https://pubmed.ncbi.nlm.nih.gov/35850122/ |
| Nascimento Osorio A, Medina Cantillo J, Camacho Salas A, Madruga Garrido M, Vilchez Padilla JJ. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. <i>Neurologia (Engl Ed)</i> . 2019;34:469-481. | https://pubmed.ncbi.nlm.nih.gov/29526319/ |
| Paganoni S, Nicholson K, Leigh F, et al. Developing multidisciplinary clinics for neuromuscular care and research. <i>Muscle Nerve</i> . 2017;56:848-858. | https://pubmed.ncbi.nlm.nih.gov/28632945/ |
| Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach. <i>Eur J Pharmacol</i> . 2023;947:175675. | https://pubmed.ncbi.nlm.nih.gov/36963652/ |
| Thomas S, Conway KM, Fapo O, et al. Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the muscular dystrophy surveillance, tracking, and research network, 2000-2015. <i>Muscle Nerve</i> . 2022;66:193-197. | https://pubmed.ncbi.nlm.nih.gov/35312090/ |
| Wilton-Clark H, Yokota T. Antisense and gene therapy options for Duchenne muscular dystrophy arising from mutations in the N-terminal hotspot. <i>Genes (Basel)</i> . 2022;13:257. | https://pubmed.ncbi.nlm.nih.gov/35205302/ |

Resources and Societies

| Resource | Address |
|--|---|
| American Academy of Neurology | https://www.aan.com/ |
| Centers for Disease Control and Prevention. Links to Other Muscular Dystrophy Resources. Last reviewed September 22, 2022. | https://www.cdc.gov/ncbddd/muscular-dystrophy/links.html |
| Cure Duchenne | https://cureduchenne.org/ |
| Muscular Dystrophy Association. Duchenne Muscular Dystrophy (DMD). | https://www.mda.org/disease/duchenne-muscular-dystrophy |
| National Society of Genetic Counselors | https://www.nsgc.org/ |
| World Duchenne Organization | https://www.worldduchenne.org/ |

All URLs accessed February 11, 2024